Literature DB >> 5006987

Malignant hyperthermia of Poland China swine: studies of a myogenic etiology.

T E Nelson, E W Jones, J H Venable, D D Kerr.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5006987     DOI: 10.1097/00000542-197201000-00009

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


× No keyword cloud information.
  19 in total

1.  Porcine malignant hyperthermia.

Authors:  T E Nelson; E W Jones; I L Anderson
Journal:  Am J Pathol       Date:  1976-07       Impact factor: 4.307

2.  Histochemical abnormalities of muscle in malignant hyperpyrexia (MH).

Authors:  H H Schiller
Journal:  Z Neurol       Date:  1973-02-26

3.  Malignant hyperthermia induced by curare.

Authors:  B A Britt; G E Webb; C LeDuc
Journal:  Can Anaesth Soc J       Date:  1974-07

4.  Malignant hyperthermia: an investigation of five patients.

Authors:  B A Britt; W Kalow; A Gordon; J G Humphrey; N B Rewcastle
Journal:  Can Anaesth Soc J       Date:  1973-07

5.  [Limited anesthetic possibilities in patients with hereditary muscular diseases].

Authors:  H Althoff
Journal:  Z Rechtsmed       Date:  1973-04-30

Review 6.  Malignant hyperthermia: molecular defects in membrane permeability.

Authors:  K S Cheah; A M Cheah
Journal:  Experientia       Date:  1985-05-15

7.  Postanesthetic myonecrosis in horses.

Authors:  S C Friend
Journal:  Can Vet J       Date:  1981-12       Impact factor: 1.008

8.  Malignant hyperthermia: a disease of specific myofiber type?

Authors:  T E Nelson; S S Schochet
Journal:  Can Anaesth Soc J       Date:  1982-03

9.  Porcine malignant hyperthermia susceptibility: increased calcium-sequestering activity of skeletal muscle sarcoplasmic reticulum.

Authors:  P J O'Brien
Journal:  Can J Vet Res       Date:  1986-07       Impact factor: 1.310

10.  Abnormality in calcium release from skeletal sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia.

Authors:  T E Nelson
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.